13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,342 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 266 - 標的パスウェイ数 : 240

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-003677-66-NL
(EUCTR)
14/02/202216/12/2021Clemastine fumarate as a treament for eye movement disorders in patients with multiple sclerosisClemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis - RESTORE Multiple sclerosis (MS)Internuclear ophthalmoparesis (INO)
MedDRA version: 21.0;Level: LLT;Classification code 10080865;Term: Multiple sclerosis lesion;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Clemastine Milstein 1 mg, tabletten
Product Name: Clemastine fumarate
INN or Proposed INN: CLEMASTINE FUMARATE
Trade Name: Fampyra 10 mg prolonged-release tablets
Product Name: Fampridine
INN or Proposed INN: Fampridine
Amsterdam University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 3Netherlands
2NCT03109288
(ClinicalTrials.gov)
August 11, 201711/4/2017Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Multiple SclerosisDrug: Pioglitazone;Drug: clemastine fumarate;Drug: Dantrolene;Drug: PirfenidoneNational Institute of Allergy and Infectious Diseases (NIAID)NULLRecruiting18 YearsN/AAll250Phase 1/Phase 2United States
3NCT02040298
(ClinicalTrials.gov)
January 201410/1/2014Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple SclerosisA Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Crossover Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDrug: Clemastine;Drug: PlaceboUniversity of California, San FranciscoNULLCompleted18 Years60 YearsBoth50Phase 2United States